NRIP1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P08574(NRIP1 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P08574(NRIP1 Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

**Background of NRIP1 Antibody**

The Nuclear Receptor Interacting Protein 1 (NRIP1), also known as RIP140 (Receptor-Interacting Protein 140), is a transcriptional coregulator that modulates the activity of nuclear receptors and other transcription factors. It plays a critical role in diverse biological processes, including energy metabolism, reproduction, and circadian rhythm regulation. NRIP1 interacts with ligand-bound nuclear receptors (e.g., estrogen receptor, thyroid hormone receptor) to either enhance or repress their transcriptional activity, depending on cellular context. Dysregulation of NRIP1 has been implicated in metabolic disorders, cancer progression, and reproductive abnormalities.

Antibodies targeting NRIP1 are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques such as Western blotting, immunoprecipitation, immunohistochemistry, and immunofluorescence to investigate NRIP1's role in cellular pathways and disease mechanisms. Commercial NRIP1 antibodies are typically raised against specific epitopes (e.g., human or mouse-derived peptide sequences) and validated for specificity and sensitivity across applications. Research utilizing these antibodies has advanced understanding of NRIP1's dual role as a coactivator or corepressor in hormone signaling and its potential as a therapeutic target in metabolic syndromes and hormone-dependent cancers. Quality validation, including knockout controls, is crucial to ensure antibody reliability in experimental settings.